Did FDA's Pain Med Warning Scare Shionogi Away From Victory?
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal to buy Victory, maker of acetaminophen-combo products, disappears into thin air soon after liver injury scare.
You may also be interested in...
FDA Panel Supports Lower Acetaminophen Dose But Spares Combo Products
In what could be a major blow to manufacturers, acetaminophen sold in 500 mg tablets will come off the OTC market if FDA follows a joint advisory committee's recommendations, but the industry may be spared the additional pain of losing combination products that include acetaminophen and other ingredients.
Deals Shaping the Medical Industry (06/2009)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.